In which situation is Rh immunoglobulin therapy typically administered?

Rh immunoglobulin therapy is typically administered to Rh-negative women during pregnancy, specifically when there is a risk of Rh isoimmunization. This occurs when an Rh-negative mother carries an Rh-positive fetus, which can lead to the mother's immune system producing antibodies against the Rh-positive blood cells. If this passage of blood occurs, it can lead to hemolytic disease in the newborn in subsequent pregnancies.

By administering Rh immunoglobulin, the mother's immune response is effectively suppressed, preventing the development of antibodies against Rh-positive blood cells. This treatment is particularly crucial during the first pregnancy and is typically given around the 28th week of gestation and again after delivery if the newborn is found to be Rh-positive.

In contrast, administering Rh immunoglobulin to all pregnant women or exclusively during the third trimester would not appropriately address the specific risk factors involved. Similarly, treating women with Rh-positive partners does not apply, as these women do not face the same risk of isoimmunization. Thus, the use of Rh immunoglobulin therapy is an essential step solely for Rh-negative women.